142 related articles for article (PubMed ID: 37247914)
1. The CCL2-CCR2 Axis Contributes to Migration of Cabazitaxel-resistant Prostate Cancer Cells.
Natsagdorj A; Izumi K; Hiratsuka K; Naito R; Kadomoto S; Iwamoto H; Yaegashi H; Shigehara K; Nakata H; Mizokami A
Anticancer Res; 2023 Jun; 43(6):2561-2569. PubMed ID: 37247914
[TBL] [Abstract][Full Text] [Related]
2. CCL2 induces resistance to the antiproliferative effect of cabazitaxel in prostate cancer cells.
Natsagdorj A; Izumi K; Hiratsuka K; Machioka K; Iwamoto H; Naito R; Makino T; Kadomoto S; Shigehara K; Kadono Y; Lin WJ; Maolake A; Mizokami A
Cancer Sci; 2019 Jan; 110(1):279-288. PubMed ID: 30426599
[TBL] [Abstract][Full Text] [Related]
3. Establishment and characterization of two cabazitaxel-resistant prostate cancer cell lines.
Machioka K; Izumi K; Kadono Y; Iwamoto H; Naito R; Makino T; Kadomoto S; Natsagdorj A; Keller ET; Zhang J; Mizokami A
Oncotarget; 2018 Mar; 9(22):16185-16196. PubMed ID: 29662635
[TBL] [Abstract][Full Text] [Related]
4. Down-regulation of E-cadherin enhances prostate cancer chemoresistance via Notch signaling.
Wang W; Wang L; Mizokami A; Shi J; Zou C; Dai J; Keller ET; Lu Y; Zhang J
Chin J Cancer; 2017 Mar; 36(1):35. PubMed ID: 28356132
[TBL] [Abstract][Full Text] [Related]
5. Docetaxel-resistant prostate cancer cells become sensitive to gemcitabine due to the upregulation of ABCB1.
Seo HK; Lee SJ; Kwon WA; Jeong KC
Prostate; 2020 May; 80(6):453-462. PubMed ID: 32134535
[TBL] [Abstract][Full Text] [Related]
6. A new flavonoid derivative exerts antitumor effects against androgen-sensitive to cabazitaxel-resistant prostate cancer cells.
Naito R; Kano H; Shimada T; Makino T; Kadomoto S; Iwamoto H; Yaegashi H; Izumi K; Kadono Y; Nakata H; Saito Y; Goto M; Nakagawa-Goto K; Mizokami A
Prostate; 2021 Apr; 81(5):295-306. PubMed ID: 33493355
[TBL] [Abstract][Full Text] [Related]
7. The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines.
Takeda M; Mizokami A; Mamiya K; Li YQ; Zhang J; Keller ET; Namiki M
Prostate; 2007 Jun; 67(9):955-67. PubMed ID: 17440963
[TBL] [Abstract][Full Text] [Related]
8. The Upregulation of PI3K/Akt and MAP Kinase Pathways is Associated with Resistance of Microtubule-Targeting Drugs in Prostate Cancer.
Liu Z; Zhu G; Getzenberg RH; Veltri RW
J Cell Biochem; 2015 Jul; 116(7):1341-9. PubMed ID: 25640606
[TBL] [Abstract][Full Text] [Related]
9. KIF14 mediates cabazitaxel-docetaxel cross-resistance in advanced prostate cancer by promoting AKT phosphorylation.
Liu L; Li M; Zhang J; Xu D; Guo Y; Zhang H; Cang S
Arch Biochem Biophys; 2023 Mar; 737():109551. PubMed ID: 36822388
[TBL] [Abstract][Full Text] [Related]
10. Molecular Mechanism Mediating Cytotoxic Activity of Cabazitaxel in Docetaxel-resistant Human Prostate Cancer Cells.
Watanabe H; Kawakami A; Sato R; Watanabe K; Matsushita Y; Miyake H
Anticancer Res; 2021 Aug; 41(8):3753-3758. PubMed ID: 34281834
[TBL] [Abstract][Full Text] [Related]
11. Targeting the androgen receptor with siRNA promotes prostate cancer metastasis through enhanced macrophage recruitment via CCL2/CCR2-induced STAT3 activation.
Izumi K; Fang LY; Mizokami A; Namiki M; Li L; Lin WJ; Chang C
EMBO Mol Med; 2013 Sep; 5(9):1383-401. PubMed ID: 23982944
[TBL] [Abstract][Full Text] [Related]
12. Skp2 is associated with paclitaxel resistance in prostate cancer cells.
Yang Y; Lu Y; Wang L; Mizokami A; Keller ET; Zhang J; Fu J
Oncol Rep; 2016 Jul; 36(1):559-66. PubMed ID: 27175797
[TBL] [Abstract][Full Text] [Related]
13. Novel α-Trifluoromethyl Chalcone Exerts Antitumor Effects Against Prostate Cancer Cells.
Shimada T; Naito R; Toriumi R; Nakagawa R; Aoyama S; Kamijima T; Kano H; Kadomoto S; Iwamoto H; Yaegashi H; Izumi K; Kadono Y; Nakata H; Saito Y; Nakagawa-Goto K; Mizokami A
Anticancer Res; 2023 Jun; 43(6):2433-2444. PubMed ID: 37247901
[TBL] [Abstract][Full Text] [Related]
14. Combination Treatment with Orlistat-Containing Nanoparticles and Taxanes Is Synergistic and Enhances Microtubule Stability in Taxane-Resistant Prostate Cancer Cells.
Souchek JJ; Davis AL; Hill TK; Holmes MB; Qi B; Singh PK; Kridel SJ; Mohs AM
Mol Cancer Ther; 2017 Sep; 16(9):1819-1830. PubMed ID: 28615298
[TBL] [Abstract][Full Text] [Related]
15. CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity.
Qian DZ; Rademacher BL; Pittsenbarger J; Huang CY; Myrthue A; Higano CS; Garzotto M; Nelson PS; Beer TM
Prostate; 2010 Mar; 70(4):433-42. PubMed ID: 19866475
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-181a promotes docetaxel resistance in prostate cancer cells.
Armstrong CM; Liu C; Lou W; Lombard AP; Evans CP; Gao AC
Prostate; 2017 Jun; 77(9):1020-1028. PubMed ID: 28485104
[TBL] [Abstract][Full Text] [Related]
17. Analysis of cabazitaxel-resistant mechanism in human castration-resistant prostate cancer.
Hongo H; Kosaka T; Oya M
Cancer Sci; 2018 Sep; 109(9):2937-2945. PubMed ID: 29989268
[TBL] [Abstract][Full Text] [Related]
18. Serum exosomal P-glycoprotein is a potential marker to diagnose docetaxel resistance and select a taxoid for patients with prostate cancer.
Kato T; Mizutani K; Kameyama K; Kawakami K; Fujita Y; Nakane K; Kanimoto Y; Ehara H; Ito H; Seishima M; Deguchi T; Ito M
Urol Oncol; 2015 Sep; 33(9):385.e15-20. PubMed ID: 26027763
[TBL] [Abstract][Full Text] [Related]
19. ABCB1 Mediates Cabazitaxel-Docetaxel Cross-Resistance in Advanced Prostate Cancer.
Lombard AP; Liu C; Armstrong CM; Cucchiara V; Gu X; Lou W; Evans CP; Gao AC
Mol Cancer Ther; 2017 Oct; 16(10):2257-2266. PubMed ID: 28698198
[TBL] [Abstract][Full Text] [Related]
20. CCL2/CCR2 axis induces hepatocellular carcinoma invasion and epithelial-mesenchymal transition in vitro through activation of the Hedgehog pathway.
Zhuang H; Cao G; Kou C; Liu T
Oncol Rep; 2018 Jan; 39(1):21-30. PubMed ID: 29115520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
